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https://doi.org/10.1016/j.jaad.2020.06.1018Multidisciplinary care of
epidermolysis bullosa during the
COVID-19 pandemic—Consensus:
Recommendations by an
international panel of expertsTo the Editor: The 2019 novel coronavirus (COVID-
19) pandemic became apparent in China during the
International Congress on Epidermolysis Bullosa
(EB) in London, in January 2020. Many patients
with EB have medical problems that make them avulnerable population of patients.1 We developed an
international consensus to suggest the best manage-
ment of patients with EB during the pandemic.
The severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) virus enters host cells using its
spike protein binding to the cell receptor angiotensin
converting enzyme 2 (ACE2), which is expressed in
several tissues. Mucosae have high ACE2 expression,
particularly the nasal epithelium. ACE2 is also
expressed in the basal layer of keratinocytes and
sebaceous glands of normal skin as well as in
vascular endothelial cells, but its expression in
wounded EB skin has not been studied.2
A questionnaire was drafted by an author (D.M.)
into a table of suggested modifications to the man-
agement of EB during the COVID-19 pandemic.
Fifty-seven well-known experts on EB were selected
based on membership of the international Clin-et
group or clinical expertise in EB, or both, demon-
strated at International EB Congress participation.
Responses and reasons for each response were
requested individually to the lead author based on
an ideal scenario, rather than what actually may
happen in some centers with financial constraints. A
priori, consensus was considered to be the agree-
ment of more than 70% of respondents with the
suggestion. Questionnaires were returned by 44 of
the 57 EB experts, representing several areas of
clinical expertise in EB (dermatology, pediatrics,
internal medicine, and surgery) from 5 continents.
After addition and revision of some items and 3
cycles of revoting, consensus was achieved for all
items, which are summarized in Supplementary
Table I (available via Mendeley at https://data.
mendeley.com/datasets/zmpncb6zpr/2).
The main change in usual practice was the
introduction of photographs from the patient/family
and teledermatology as the primary visit for patients
with less severe EB, with dressing supplies sent to the
patients directly. For those patients with EB with
significant internal disease, monitoring tests
(blood and urine) must continue but can be obtained
by local laboratories or family doctors close to
home.3 If telehealth images are insufficient to
assess lesions, assessments should be conducted at
the EB center.4
One of the greatest fears of families caring for
patients with severe forms of EB is how they will be
perceived on admission to hospitals, especially in-
stitutions with limited resources, including ventila-
tors. Because patients with EB often appear frail and
emaciated, health care workers unfamiliar with the
condition may underestimate their resilience and
incorrectly assume that they have a low likelihood of
survival.5 If a patient with EB required
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Research Letters 1223anticoagulation to manage COVID-19, there might
be additional bleeding from the skin or mucosae, but
blood transfusions will compensate for this.
Supplemental Table I details protection for the skin
and mucosae that is required for wearing masks and
ventilation.
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https://doi.org/10.1016/j.jaad.2020.06.1023Fighting COVID-19: Early
teledermatology lessons learnedTo the Editor: Coronavirus disease 2019 (COVID-
19) has exacerbated the unequal access to medical
care experienced by historically marginalized pa-
tient populations.1 Early data demonstrate that the
infection and death rates in predominantly black
neighborhoods are 3-fold and 6-fold higher,
respectively, than in predominantly white neigh-
borhoods.2 In response to the pandemic, academic
and private dermatology practices have both
quickly rolled out teledermatology service in an
effort to continue access to care. Our study
evaluated early practice patterns to identify any
variations in the quality of and access to tele-
dermatology services.
We randomly selected 274 teledermatology visits
conducted during the month of April 2020 in
the Department of Dermatology at Beth Israel
Deaconess Medical Center. We reviewed each visit
and extracted the following information: age,
preferred language, diagnoses, disposition, visit
type (telephone vs video), and visit duration. In
addition, we randomly selected 250 in-person visits
conducted during the month of February 2020 for a
prepandemic comparison.
Before the pandemic, 32% of patients seen in
person were older than 65 years, and 7% of patients
seen in person were noneEnglish speaking, those
defined as necessitating interpreter service (Table I).
During the pandemic, 23% of patients seen in tele-
dermatology were older than 65 years, and 3% of
patients seen in teledermatology were noneEnglish
speaking (Table I).
The 2 most common diagnoses seen in tele-
dermatology, other than a lesion of concern, were
acne at 19% and dermatitis at 18% of total visits
(Table II). Nearly all teledermatology visits with
these diagnoses led to a recommendation for
discharge or follow-up via subsequent teledermatol-
ogy visits. In contrast, 60% of teledermatology visits
for evaluation of lesion(s) led to a recommendation
to follow-up in person for re-evaluation or biopsy, or
both. Lastly, 75% of teledermatology visits with
durations of 20 minutes or greater were conducted
